Last reviewed · How we verify
Hib (Hiberix™)
Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) polysaccharide capsule.
Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) polysaccharide capsule. Used for Prevention of invasive Haemophilus influenzae type b disease in infants and children.
At a glance
| Generic name | Hib (Hiberix™) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Target | Haemophilus influenzae type b polysaccharide capsule (PRP) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified Hib polyribosyl ribitol phosphate (PRP) polysaccharide conjugated to meningococcal protein to enhance immunogenicity. This conjugation allows T-cell dependent immune responses, resulting in robust antibody production and immunological memory against Hib infection. The vaccine prevents invasive Hib disease including meningitis, epiglottitis, and bacteremia.
Approved indications
- Prevention of invasive Haemophilus influenzae type b disease in infants and children
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) (PHASE3)
- Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
- Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (PHASE4)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine (PHASE3)
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants (PHASE2)
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hib (Hiberix™) CI brief — competitive landscape report
- Hib (Hiberix™) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI